Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.82 USD | -3.22% | -1.26% | -31.64% |
Sales 2024 * | 448M 613M | Sales 2025 * | 494M 675M | Capitalization | 1.24B 1.7B |
---|---|---|---|---|---|
Net income 2024 * | 106M 145M | Net income 2025 * | 139M 190M | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.52 x |
P/E ratio 2024 * |
10.1
x | P/E ratio 2025 * |
8.89
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.43% |
Latest transcript on Ironwood Pharmaceuticals, Inc.
1 day | -3.22% | ||
1 week | -1.26% | ||
Current month | -10.22% | ||
1 month | -9.28% | ||
3 months | -41.60% | ||
6 months | -11.04% | ||
Current year | -31.64% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas McCourt
CEO | Chief Executive Officer | 66 | 08-12-31 |
Sravan Emany
DFI | Director of Finance/CFO | 46 | 21-12-05 |
Marcel Moulaison
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexander Denner
BRD | Director/Board Member | 54 | 20-11-08 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-12-02 |
Mark Currie
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.50% | 29 M€ | -4.33% | ||
0.42% | 27 M€ | -5.03% | - | |
0.35% | 1,026 M€ | +6.95% | - | |
0.20% | 45 M€ | +0.20% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 7.82 | -3.22% | 2,782,956 |
24-04-25 | 8.08 | -0.25% | 2,674,832 |
24-04-24 | 8.1 | -2.53% | 1,853,345 |
24-04-23 | 8.31 | +3.10% | 2,539,491 |
24-04-22 | 8.06 | +1.77% | 2,765,675 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.64% | 1.24B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IRWD Stock